(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Syrian army says recent drone attacks targeted its bases near Iraq, most shot down - 2Image of foreigners being arrested in S.Africa during Eid is AI-generated
- 3‘Nahariya get ready’: Banner displaying Hezbollah threat mounted in Tehran’s Palestine Square
- 4Amid Iran war, 53 of Israel's future scientists showcase projects in Jerusalem contest
- 5the 6 Shrewd Beds for seniors: A Complete Survey
- China's Normal Ponders: A Visual Excursion
- Public Parks in the USA
- A definitive Burger Confrontation: Which One Rules?
- Songbirds swap colorful plumage genes across species lines among their evolutionary neighbors
- Renewables cover over 50% of German electricity consumption in Q1
- Aspect Biosystems receives funding for cellular medicine project
- Hamas demanded displaced Gazans pay rent on beach tents amid torrential downpour, IDF reveals
- 10 Hints and Deceives to Expand Cell Phone Information Use: Capitalize on Your Information
- Energy security rifts widen in Europe
